These ratios are important while doing valuation of the company or the shares of the company.
A number of other equities analysts also recently issued reports on the company. HL Financial Services LLC increased its holdings in Endo International PLC by 1.0% in the 2nd quarter. The stock traded within a range of $7.40 and $7.75. Riverhead Capital Management LLC lifted its holdings in Endo International PLC by 64.4% in the second quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company's stock valued at $32,065,000 after acquiring an additional 1,857,678 shares during the period. During the same period in the prior year, the business posted $0.86 EPS. Acadian Asset Management LLC now controls 428 shares with a value of $4,000. Finally, Schneider Capital Management Corp lifted its holdings in Endo International PLC by 14.9% in the first quarter. Arizona State Retirement System now owns 83,700 shares of the company's stock valued at $935,000 after purchasing an additional 1,200 shares in the last quarter.
Several analysts recently issued reports on ENDP shares.
On August 9 Deutsche Bank maintained a company rating of "Buy" and moved down the price target from $65.00 to $13.00. The brokerage now has a "hold" rating on the stock. Royal Bank Of Canada set a $15.00 price target on Endo International PLC and gave the company a "hold" rating in a report on Sunday, July 16th. ValuEngine downgraded Endo International PLC from a "buy" rating to a "hold" rating in a research note on Friday, September 1st. August 10 investment analysts at Morgan Stanley held the stock rating at "Buy" but lowered the price expectation to $13.00 from $85.00.
ILLEGAL ACTIVITY WARNING: This news story was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another domain, it was copied illegally and republished in violation of worldwide trademark and copyright legislation.
The correct version of this news story can be viewed at https://weekherald.com/2017/10/18/piedmont-investment-advisors-llc-buys-17928-shares-of-endo-international-plc-endp.html.
Endo International plc (NASDAQ:ENDP) shares have experienced a recent steady downtrend, causing some concern for shareholders. 288,401 shares of the stock traded hands.
The market capitalization of Endo International plc is at $1.72 Billion. The firm has a 50-day moving average of $8.67 and a 200 day moving average of $10.54. Endo International PLC has a 52 week low of $7.41 and a 52 week high of $23.98.
Endo International plc (ENDP) is expected to post revenue of $775.26 Million in the current quarter, according to consensus of 16 analysts. Previously Endo Int'l Plc (NASDAQ:ENDP) reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.2 with surprise factor of 27.4%. The company had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million.
Endo International plc (NASDAQ:ENDP) gross margin percentage stands at 37.6% while its operating margin for the past trailing twelve month is -99.9 percent and its overall profit margin (ttm) is 0 Percent. The company's average Piotroski F-Score: 4 during the last 7 years. "Similarly, the company's EVP, Chief Legal Officer Maletta Matthew Joseph on 2017-08-15 Buy 3000 shares of the company at a price of $8.02". To make a proper assessment, investors seek a sound estimate of this year's and next year's earnings per share (EPS), as well as a strong sense of how much the company will earn even farther down the road.
In other Endo International PLC news, COO Terrance J. Coughlin bought 20,000 shares of the business's stock in a transaction on Thursday, August 10th. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The shares were acquired at an average price of $7.70 per share, for a total transaction of $154,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 36,000 shares of company stock worth $279,460.
The company now has an insider ownership of 0.5 Percent and Institutional ownership of 89.2 Percent.
Endo International plc is a global specialty healthcare company. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology.